APLEX Bio develops Hyperplex PCR™ technology for analyzing massive numbers of biomarkers (100+ targets in a single well) for diagnostics.

Amplified Sciences is a clinical-stage life science diagnostics company focused on detecting and monitoring serious, challenging diseases, such as pancreatic cancer. The company utilizes a proprietary ultra-sensitive optical reporter platform (BioMatra™) licensed from Purdue University to improve early detection and risk stratification.

Ambrosia Biosciences is developing orally delivered, small-molecule therapies for obesity and metabolic disorders. Led by former Array BioPharma scientists, the company utilizes AI-powered molecular design and structural biology to target GPCRs.

Provide research peptides and compatible solutions for laboratory applications. Sourced for purity and professional research use.

Vipergen specializes in small molecule drug discovery using proprietary DNA-encoded library (DEL) technologies. They offer services for screening, including the unique capability to screen in living cells, aiming to identify novel drug leads.

Virtual Discovery, Inc. specializes in AI-driven, customized drug discovery services. They utilize VirtualFlow, a tool developed for molecular docking to traverse large chemical spaces of over 60 billion molecules, particularly for small molecule and hit generation.

Examol is a biotechnology company focused on accelerating drug discovery using artificial intelligence, quantum chemistry, and high-performance computing.

Lotus Separations provides chiral and achiral chromatographic purification services for small molecules, including SFC, HPLC, and NMR methods for the pharmaceutical industry

Visikol is a contract research services company and manufacturer specializing in advanced tissue imaging, 3D cell culture (spheroids, organoids), and digital pathology to accelerate drug discovery. In April 2025, it was announced that Visikol was acquired by Sartorius. 

Chemspace is an online marketplace and supplier of small molecules, building blocks, and drug discovery services, featuring a database of over 13 billion molecules. It acts as a bridge between chemical vendors (such as Enamine, Cambridge, and others) and researchers in the pharmaceutical industry, offering in-stock compounds and "make-on-demand" analogs.